Bufo vs Psilocybin: What Actually Differs

Two of the most discussed psychedelic therapies get filed under the same heading constantly, and they could hardly be less alike. Bufo — shorthand for 5-MeO-DMT, the compound found in the secretion of the Sonoran Desert toad — produces an experience measured in minutes. Psilocybin, the compound in Psilocybe mushrooms, unfolds across most of a day.

People researching both usually arrive asking which one is stronger. That turns out to be the wrong question. The more useful one is which kind of experience a person is actually prepared for, and which one a physician would clear them for after reviewing their history.

What is bufo, and what is psilocybin?

Bufo refers to 5-methoxy-N,N-dimethyltryptamine, a short-acting tryptamine present in the parotoid gland secretion of Incilius alvarius, the Sonoran Desert toad — an animal long catalogued under the older name Bufo alvarius, which is where the street shorthand comes from. The same molecule can be produced synthetically, and the choice between secretion-derived and synthetic material has become a real consideration for both purity and toad conservation. A supervised bufo program handles that sourcing question as part of its protocol rather than leaving it to chance.

Psilocybin is a different tryptamine, produced by more than two hundred species of fungi. The body converts it to psilocin, which is the active form. Where 5-MeO-DMT is vaporised and inhaled, psilocybin is nearly always taken orally, which is a large part of why the two unfold on such different timescales.

Both act on serotonin receptors, but not identically. Psilocin has a well-characterised affinity for the 5-HT2A receptor, the site most closely associated with classic psychedelic effects. 5-MeO-DMT is comparatively more active at 5-HT1A. That pharmacological difference is not a footnote — it maps onto the very different subjective character of the two experiences, and onto which medications a physician will want to review before either one.

How long does each experience last?

This is the single largest practical difference. An inhaled 5-MeO-DMT experience typically begins within seconds and resolves within roughly ten to twenty minutes, with a settling period afterward. There is no gradual onset to prepare during, and no long plateau to work through.

Oral psilocybin is the opposite shape. Onset generally takes twenty to sixty minutes, the peak occupies the middle hours, and the whole arc commonly runs four to six hours before returning to baseline. That length is why psilocybin research protocols are built around a full session day with a facilitator present throughout.

The consequence for planning is straightforward. A bufo session is short but front-loaded: almost everything that matters happens in preparation beforehand and integration afterward. A psilocybin therapy retreat inverts that ratio, asking for sustained presence during the session itself.

What does a session actually look like?

With psilocybin, there is room to work inside the experience. Participants can speak, be redirected, ask for reassurance, change position, listen to a curated music programme. Facilitators can intervene in real time. Much of the therapeutic literature treats that interactive window as a core feature rather than an accident of pharmacology.

With bufo, that window essentially does not exist. Onset is fast enough that verbal support during the peak is not meaningful. Participants are typically reclined and physically supported before administration, and the facilitator's job shifts almost entirely to safety monitoring and to what happens in the minutes and hours after. The work moves to either side of the session rather than into it.

Reported phenomenology differs too. Psilocybin experiences are frequently described in visual and narrative terms — imagery, memory, emotional material surfacing in sequence. 5-MeO-DMT is more often described as non-narrative and non-visual, a dissolution of the ordinary sense of a separate self with little content to recount afterward. Neither description is universal, and individual variation is wide.

That difference shapes integration. People often leave a psilocybin session with specific material to work through in therapy. People often leave a bufo session with something harder to put into language, which is why structured integration support matters and why some programmes pair the two modalities rather than treating them as substitutes.

The staffing implications differ as well. A psilocybin session day requires a facilitator or facilitator pair committed for the full duration, trained to sit with distress without intervening prematurely. A bufo session requires fewer hours but a different competency set — airway management, vital-sign monitoring, and the physical handling of someone who is briefly unresponsive and unable to protect themselves. Asking a provider which of these their staff are actually trained for is a reasonable question, and the answer is informative.

What is each compound being studied for?

Psilocybin has the deeper clinical record of the two. Research groups including Johns Hopkins University and Imperial College London have run controlled trials examining psilocybin-assisted therapy for treatment-resistant depression, major depressive disorder, end-of-life distress in people with serious illness, and alcohol and tobacco use disorders. Several of those programmes have advanced into later-stage trials. The findings are genuinely promising and also genuinely provisional — trial populations have been small and carefully screened, and no regulator has approved psilocybin as a general medical treatment.

The 5-MeO-DMT literature is considerably thinner. Most of what exists is observational: survey work and small open-label studies looking at self-reported changes in depressive and anxiety symptoms after ceremonial or clinical administration. Controlled trials are underway but the evidence base does not yet support confident claims about outcomes for any condition.

What that asymmetry means in practice is that neither compound should be described as a cure, and bufo especially should not be described as a proven treatment. Anyone presenting either one as a guaranteed outcome is describing something the research does not currently establish. The honest framing is that both are being investigated, that reported experiences are often significant to the people who have them, and that the durability of any change depends heavily on what follows the session.

How does medical screening differ?

Screening for both begins in the same place — a full medical and psychiatric history, current medications and supplements, cardiovascular status, and personal and family history of psychosis or bipolar disorder. Beyond that shared floor, the emphases diverge.

For psilocybin, the medication review centres on serotonergic agents. SSRIs, SNRIs, MAOIs, lithium, and tricyclics all interact with psilocybin's mechanism in different ways, and some require a supervised taper well in advance of a session. Lithium in particular has been associated with serious adverse events in combination with classic psychedelics. None of that is something to work out alone; it belongs with the prescribing physician, and a responsible programme will want documentation rather than a verbal assurance.

For bufo, cardiovascular screening carries additional weight. The onset is abrupt and the associated cardiovascular and respiratory response is correspondingly rapid, which makes baseline blood pressure, cardiac history, and respiratory conditions such as poorly controlled asthma central to the intake. MAOIs deserve specific attention here, because combining a monoamine oxidase inhibitor with 5-MeO-DMT can prolong and intensify effects in ways that are difficult to manage. Airway positioning and continuous monitoring are part of the protocol precisely because the window is so short.

Psychiatric screening is where the two overlap most and where the stakes are highest. A personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I is treated as a serious contraindication for both compounds, because both can precipitate or worsen psychotic and manic episodes. This is not a matter of dosing carefully around it.

Our clinical team reviews medication lists, cardiac history, and psychiatric history before anyone is accepted for either modality, and some people are appropriately declined. Our page on 5-MeO-DMT safety and contraindications sets out what that screening covers before you make any decision.

One practical note that catches people out: supplements count. St John's wort, 5-HTP, SAM-e, and high-dose tryptophan all act on serotonergic pathways, and they belong on the disclosure list alongside prescriptions. So does anything taken irregularly — a sleep aid, a migraine triptan, a leftover course of something. Programmes that ask only about daily prescriptions are asking an incomplete question.

Which one fits where you are?

There is no ranking to apply here, but there are reasonable orientations.

Psilocybin tends to suit people who want to work with specific material — a grief, a pattern, a depression that has resisted other approaches — and who can commit to a long session and the therapy around it. The longer arc is the point.

Bufo tends to draw people who have already done extended psychedelic work and are looking for something different in kind rather than in degree. Its brevity makes it logistically simpler and psychologically harder to prepare for, because there is no warm-up. It is generally a poor first step for someone with no prior experience and no established support structure.

Two practical filters cut through most of the deliberation. First, what does your cardiac and medication picture allow? That answer comes from screening, not preference. Second, what support will exist in the weeks after — not the day after? A short bufo session with no integration plan is a worse use of the experience than a well-supported psilocybin session, and the reverse holds too.

If you are weighing the two, the most useful next step is a conversation with a clinician who can look at your actual history rather than a general comparison. The medical team at MindScape Retreat's clinic in Cozumel reviews candidacy for both modalities as part of a single screening process, so you can find out what is genuinely available to you before committing to anything. Reach out for a consultation and bring your medication list with you.

---

This article is educational and is not medical advice. Psychedelic therapies carry real medical risk and are not appropriate for everyone. Discuss any decision with a qualified physician who knows your history. If you are in crisis in the United States, call or text 988.